Getting 'Smad' about obesity and diabetes

Nutrition and Diabetes

Volumn 2, Issue MARCH, 2012, Pages

  Tan, C K ^a   Chong, H C ^a   Tan, E H P ^a   Tan, N S ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Insulin resistance; Metabolism; Obesity; Smad3; TGF b

Indexed keywords

ACARBOSE; ADIPOCYTOKINE; CCAAT ENHANCER BINDING PROTEIN BETA; CCAAT ENHANCER BINDING PROTEIN DELTA; CYCLIC AMP; GLUCOCORTICOID; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 6; LEPTIN; MESSENGER RNA; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYOGENIC FACTOR 5; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; RETINOL BINDING PROTEIN 4; SMAD2 PROTEIN; SMAD3 PROTEIN; SULFONYLUREA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ADRENERGIC STIMULATION; ALLOSTERISM; AMINO ACID SEQUENCE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIDIABETIC ACTIVITY; BLADDER CANCER; BODY FAT; BODY MASS; BROWN ADIPOSE TISSUE; CALORIC INTAKE; CANCER RISK; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL ENERGY; CELL FUNCTION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COHORT ANALYSIS; COLD EXPOSURE; CYSTIC FIBROSIS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DISEASE COURSE; DYSLIPIDEMIA; EMBRYO DEVELOPMENT; ENERGY BALANCE; ENERGY EXPENDITURE; ENVIRONMENTAL STRESS; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ASSOCIATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; GROWTH RETARDATION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEPATITIS; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPOXIA; IMMUNE DEFICIENCY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY CELL; INSULIN ALLERGY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN SYNTHESIS; INTRAABDOMINAL FAT; KNOCKOUT MOUSE; LETHALITY; LIPID DIET; LIPID METABOLISM; LIPID STORAGE; LIPOTOXICITY; LONG TERM EXPOSURE; LONGITUDINAL STUDY; METABOLIC SYNDROME X; MORBID OBESITY; MUSCLE ATROPHY; MUSCLE HYPERTROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PHENOTYPE; PHYSICAL ACTIVITY; PLEIOTROPY; POSTNATAL GROWTH; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; REVIEW; SATELLITE CELL; SCLERODERMA; TERATOGENICITY; THERMAL EXPOSURE; THERMOGENESIS; TRANSGENIC MOUSE; ULTRAVIOLET RADIATION; WEIGHT GAIN; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE; WOUND HEALING;

EID: 84880748325     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2012.1     Document Type: Review

References (120)

1. Kopelman PG, Albon L. Obesity, non-insulin-dependent diabetes mellitus and the metabolic syndrome. Br Med Bull 1997; 53: 322-340.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
3. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-846.
4. Tan CK, Leuenberger N, Tan MJ, Yan YW, Chen Y, Kambadur R et al. Smad3 deficiency in mice protects against insulin resistance and obesity induced by a high-fat diet. Diabetes 2011; 60: 464-476.
5. Yadav H, Quijano C, Kamaraju AK, Gavrilova O, Malek R, Chen W et al. Protection from obesity and diabetes by blockade of TGF-b/Smad3 signaling. Cell Metab 2011; 14: 67-79.
6. Tsurutani Y, Fujimoto M, Takemoto M, Irisuna H, Koshizaka M, Onishi S et al. The roles of transforming growth factor-b and Smad3 signaling in adipocyte differentiation and obesity. Biochem Biophys Res Commum 2011; 407: 68-73.
7. Lin HM, Lee JH, Yadav H, Kamaraju AK, Liu E, Zhigang D et al. Transforming growth factor-beta/Smad3 signaling regulates insulin gene transcription and pancreatic islet beta-cell function. J Biol Chem 2009; 284: 12246-12257.
8. MassaguéJ, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295-309.
9. Shi Y, MassaguéJ. Mechanisms of TGF-b signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700.
10. Mori S, Matsuzaki K, Yoshida K, Furukawa F, Tahashi Y, Yamagata H et al. TGFbeta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene 2004; 23: 7416-7429.
11. Brown KA, Pietenpol JA, Moses HL. A tale of two proteins: Differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell Biochem 2007; 101: 9-33.
12. Heyer J, Escalante-Alcalde D, Lia M, Boettinger E, Edelmann W, Stewart CL et al. Postgastrulation Smad2-deficient embryos show defects in embryo turning and anterior morphogenesis. Proc Natl Acad Sci USA 1999; 96: 12595-12600.
13. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J 1999; 18: 1280-1291.
14. Ashcroft GS, Mills SJ, Flanders KC, Lyakh LA, Anzano MA, Gilliver SC et al. Role of Smad3 in the hormonal modulation of in vivo wound healing responses. Wound Repair Regen 2003; 11: 468-473.
15. Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 2004; 85: 47-64.
16. Alessi MC, Bastelica D, Morange P, Berthet B, Leduc I, Verdier M et al. Plasminogen activator inhibitor 1, transforming growth factor-beta 1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000; 49: 1374-1380.
17. Gordon KJ, Blobe GC. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta 2008; 1782: 197-228.
18. Herder C, Zierer A, Koenig W, Roden M, Meisinger C, Thorand B. Transforming growth factor-beta1 and incident type 2 diabetes: Results from the MONICA/KORA case-cohort study, 1984-2002. Diabetes Care 2009; 32: 1921-1923.
19. Perry JR, McCarthy MI, Hattersley AT, Zeggini E, Weedon MN, Frayling TM. Interrogating type 2 diabetes genome-wide association data using a biological pathway-based approach. Diabetes 2009; 58: 1463-1467.
20. Wu L, Derynck R. Essential role of TGF-beta signaling in glucose-induced cell hypertrophy. Dev Cell 2009; 17: 35-48.
21. Rosmond R, Chagnon M, Bouchard C, Björntorp P. Increased abdominal obesity, insulin and glucose levels in nondiabetic subjects with a T29C polymorphism of the transforming growth factor-beta1 gene. Horm Res 2003; 59: 191-194.
22. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 1999; 8: 93-97.
23. Yu SK, Kwon OS, Jung HS, Bae KS, Kwon KA, Kim YK et al. Influence of transforming growth factor-beta1 gene polymorphism at codon 10 on the development of cirrhosis in chronic hepatitis B virus carriers. J Korean Med Sci 2010; 25: 564-569.
24. Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnik BR et al. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 1997; 46: 854-859.
25. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000; 97: 8015-8020.
26. Han DC, Hoffman BB, Hong SW, Guo J, Ziyadeh FN. Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Am J Physiol Renal Physiol 2000; 278: F628-F634.
27. Rosen ED, Hsu CH, Wang X, Sakai S, Freeman MW, Gonzalez FJ et al. C/EBPalpha induces adipogenesis through PPARgamma: A unified pathway. Genes Dev 2002; 16: 22-26.
28. Choy L, Derynck R. Transforming growth factor-beta inhibits adipocyte differentiation by Smad3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function. J Biol Chem 2003; 278: 9609-9619.
29. Marchildon F, St-Louis C, Akter R, Roodman V, Wiper-Bergeron NL. Transcription factor Smad3 is required for the inhibition of adipogenesis by retinoic acid. J Biol Chem 2010; 285: 13274-13284.
30. Berry DC, Soltanian H, Noy N. Repression of cellular retinoic acid-binding protein II during adipocyte differentiation. J Biol Chem 2010; 285: 15324-15332.
31. Imai T, Takakuwa R, Marchand S, Dentz E, Bornert JM, Messaddeq N et al. Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse. Proc Natl Acad Sci USA 2004; 101: 4543-4547.
32. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H et al. Peroxisome- proliferatoractivated receptor delta activates fat metabolism to prevent obesity. Cell 2003; 113: 159-170.
33. Ron D, Habener JF. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev 1992; 6: 439-453.
34. Medina-Gomez G, Gray SL, Yetukuri L, Shimomura K, Virtue S, Campbell M et al. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet 2007; 3: E64.
35. Jacob S, Machann J, Rett K, Brechtel K, Volk A, Renn W et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 1999; 48: 1113-1119.
36. Schuler M, Ali F, Chambon C, Duteil D, Bornert JM, Tardivel A et al. PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab 2006; 4: 407-414.
37. Luquet S, Lopez-Soriano J, Holst D, Fredenrich A, Melki J, Rassoulzadegan M et al. Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J 2003; 17: 2299-2301.
38. Ge X, McFarlane C, Vajjala A, Lokireddy S, Ng ZH, Tan CK et al. Smad3 signaling is required for satellite cell function and myogenic differentiation of myoblasts. Cell Res 2011; 21: 1591-1604.
39. Pearen MA, Ryall JG, Lynch GS, Muscat GE. Expression profiling of skeletal muscle following acute and chronic beta2-adrenergic stimulation: Implications for hypertrophy, metabolism and circadian rhythm. BMC Genomics 2009; 10: 448.
40. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11: 327-332.
41. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B. Rat PPARs: Quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001; 142: 4195-4202.
42. Vidal-Puig A, Jimenez-Linan M, Lowell BB, Hamann A, Hu E, Spiegelman B et al. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest 1996; 97: 2553-2561.
43. Kruszynska YT, Mukherjee R, Jow L, Dana S, Paterniti JR, Olefsky JM. Skeletal muscle peroxisome proliferator-activated receptor-gamma expression in obesity and non-insulin-dependent diabetes mellitus. J Clin Invest 1998; 101: 543-548.
44. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99: 2416-2422.
45. Seale P, Kajimura S, Yang W, Chin S, Rohas LM, Uldry M et al. Transcriptional control of brown fat determination by PRDM16. Cell Metab 2007; 6: 38-54.
46. Seale P, Bjork B, Yang W, Kajimura S, Chin S, Kuang S et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature 2008; 454: 961-967.
47. Atit R, Sgaier SK, Mohamed OA, Taketo MM, Dufort D, Joyner AL et al. Betacatenin activation is necessary and sufficient to specify the dorsal dermal fate in the mouse. Dev Biol 2006; 296: 164-176.
48. Enerbäck S. The origins of brown adipose tissue. N Engl J Med 2009; 360: 2021-2023.
49. Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr 2005; 81: 555-563.
50. Seale P, Conroe HM, Estall J, Kajimura S, Frontini A, Ishibashi J et al. Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. J Clin Invest 2011; 121: 96-105.
51. Scim A, Grenier G, Huh MS, Gillespie MA, Bevilacqua L, Harper ME et al. Rb and p107 regulate preadipocyte differentiation into white versus brown fat through repression of PGC-1alpha. Cell Metab 2005; 2: 283-295.
52. Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U et al. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol 2002; 283: H1253-H1262.
53. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993; 42: 1663-1672.
54. Tripathy D, Eriksson KF, Orho-Melander M, Fredriksson J, Ahlqvist G, Groop L. Parallel manifestation of insulin resistance and beta cell decompensation is compatible with a common defect in Type 2 diabetes. Diabetologia 2004; 47: 782-793.
55. Sako Y, Grill VE. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 1990; 127: 1580-1589.
56. Zhou YP, Grill VE. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 1994; 93: 870-876.
57. Petersen KF, Shulman GI. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 11G-18G.
58. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)- associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002; 277: 50230-50236.
59. Björntorp P. 'Portal' adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10: 493-496.
60. Lam TK, van de Werve G, Giacca A. Free fatty acids increase basal hepatic glucose production and induce hepatic insulin resistance at different sites. Am J Physiol Endocrinol Metab 2003; 284: E281-E290.
61. Conery AR, Cao Y, Thompson EA, Townsend Jr CM, Ko TC, Luo K. Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis. Nat Cell Biol 2004; 6: 366-372.
62. Taura N, Ichikawa T, Hamasaki K, Nakao K, Nishimura D, Goto T et al. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol 2006; 101: 2752-2759.
63. Lee MS, Gu D, Feng L, Curriden S, Arnush M, Krahl T et al. Accumulation of extracellular matrix and developmental dysregulation in the pancreas by transgenic production of transforming growth factor-beta 1. Am J Pathol 1995; 147: 42-52.
64. Kim S, Moustaid-Moussa N. Secretory, endocrine and autocrine/paracrine function of the adipocyte. J Nutr 2000; 130: 3110S-3115S.
65. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
66. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
67. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008; 14: 741-751.
68. Guzik TJ, Mangalat D, Korbut R. Adipocytokines - novel link between inflammation and vascular function? J Physiol Pharmacol 2006; 57: 505-528.
69. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93: S64-S73.
70. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007; 92: 1023-1033.
71. Di Gregorio GB, Yao-Borengasser A, Rasouli N, Varma V, Lu T, Miles LM et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: Association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 2005; 54: 2305-2313.
72. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436: 356-362.
73. Berry DC, Jin H, Majumdar A, Noy N. Signaling by vitamin A and retinol-binding protein regulates gene expression to inhibit insulin responses. Proc Natl Acad Sci USA 2011; 108: 4340-4345.
74. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117: 175-184.
75. Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM, Neels JG. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab 2008; 8: 301-309.
76. Brown JE, Onyango DJ, Ramanjaneva M, Conner AC, Patel ST, Dunmore SJ et al. Visfatin regulates insulin secretion, insulin receptor signaling and mRNA expression of diabetes-related genes in mouse pancreatic beta-cells. J Mol Endocrinol 2010; 44: 171-178.
77. Kusminski CM, McTernan PG, Kumar S. Role of resistin in obesity, insulin resistance and Type II diabetes. Clin Sci (Lond) 2005; 109: 243-256.
78. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2005; 334: 1092-1101.
79. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000; 11: 212-217.
80. Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 2000; 275: 15985-15991.
81. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: The good, the bad, or the indifferent? Diabetes 2005; 54 (Suppl 2): S114-S124.
82. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003; 100: 7265-7270.
83. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494-1505.
84. Ma J, Wang Q, Fei T, Han JD, Chen YG. MCP-1 mediates TGF-beta-induced angiogenesis by stimulating vascular smooth muscle cell migration. Blood 2007; 109: 987-994.
85. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: Possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-867.
86. Song CZ, Siok TE, Gelehrter TD. Smad4/DPC4 and Smad3 mediate transforming growth factor-beta (TGF-beta) signaling through direct binding to a novel TGF-beta-responsive element in the human plasminogen activator inhibitor-1 promoter. J Biol Chem 1998; 273: 29287-29290.
87. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996; 382: 250-252.
88. Fernández-Riejos P, Najib S, Santos-Alvarez J, Martín-Romero C, Pérez-Pérez A, González-Yanes C et al. Role of leptin in the activation of immune cells. Mediators Inflamm 2010; 2010: 568343.
89. Wanninger J, Neumeier M, Hellerbrand C, Schacherer D, Bauer S, Weiss TS et al. Lipid accumulation impairs adiponectin-mediated induction of activin A by increasing TGFbeta in primary human hepatocytes. Biochim Biophys Acta 2011; 1811: 626-633.
90. Bahceci M, Gokalp D, Bahceci S, Tuzcu A, Atmaca S, Arikan S. The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults? J Endocrinol Invest 2007; 30: 210-214.
91. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-1792.
92. Sekiguchi K, Tian Q, Ishiyama M, Burchfield J, Gao F, Mann DL et al. Inhibition of PPAR-alpha activity in mice with cardiac-restricted expression of tumor necrosis factor: Potential role of TGF-beta/Smad3. Am J Physiol Heart Circ Physiol 2007; 292: H1443-H1451.
93. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
94. Afanas'ev I. Signaling of reactive oxygen and nitrogen species in Diabetes mellitus. Oxid Med Cell Longev 2010; 3: 361-373.
95. Urakawa H, Katsuki A, Sumida Y, Gabazza EC, Murashima S, Morioka K et al. Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Metab 2003; 88: 4673-4676.
96. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-1761.
97. Lin Y, Berg AH, Iyengar P, Lam TK, Giacca A, Combs TP et al. The hyperglycemiainduced inflammatory response in adipocytes: The role of reactive oxygen species. J Biol Chem 2005; 280: 4617-4626.
98. Yang S, Zhu H, Li Y, Lin H, Gabrielson K, Trush MA et al. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 2000; 378: 259-268.
99. Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997; 69: 2064-2074.
100. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006; 440: 944-948.
101. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-336.
102. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005; 120: 649-661.
103. Lee YH, Giraud J, Davis RJ, White MF. c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J Biol Chem 2003; 278: 2896-2902.
104. Engel ME, McDonnell MA, Law BK, Moses HL. Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. J Biol Chem 1999; 274: 37413-37420.
105. Michaeloudes C, Sukkar MB, Khorasani NM, Bhavsar PK, Chung KF. TGF-b regulates Nox4, MnSOD and catalase expression, and IL-6 release in airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2011; 300: L295-L304.
106. Black D, Lyman S, Qian T, Lemasters JJ, Rippe RA, Nitta T et al. Transforming growth factor beta mediates hepatocyte apoptosis through Smad3 generation of reactive oxygen species. Biochimie 2007; 89: 1464-1473.
107. Zhang H, Akman HO, Smith EL, Zhao J, Murphy-Ullrich JE, Batuman OA. Cellular response to hypoxia involves signaling via Smad proteins. Blood 2003; 101: 2253-2260.
108. Collier CA, Bruce CR, Smith AC, Lopaschuck G, Dyck DJ. Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle. Am J Physiol Endocrinol Metab 2006; 291: E182-E189.
109. Chao L, Marcus-Samuels B, Mason MM, Moitra J, Vinson C, Arioglu E et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 2000; 106: 1221-1228.
110. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003; 115 (Suppl 8A): 42S-48S.
111. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry Jr CP et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916-922.
112. Jinnin M, Ihn H, Tamaki K. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol 2006; 69: 597-607.
113. Campistol JM, Inigo P, Jimenez W, Lario S, Clesca PH, Oppenheimer F et al. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999; 56: 714-719.
114. Hondares E, Rosell M, Díaz-Delfín J, Olmos Y, Monsalve M, Iglesias R et al. Peroxisome proliferator-activated receptor a (PPARa) induces PPARc coactivator 1a (PGC-1a) gene expression and contributes to thermogenic activation of brown fat: Involvement of PRDM16. J Biol Chem 2011; 286: 43112-43122.
115. Barbera MJ, Schluter A, Pedraza N, Iglesias R, Villarroya F, Giralt M. Peroxisome proliferator-activated receptor alpha activates transcription of the brown fat uncoupling protein-1 gene. A link between regulation of the thermogenic and lipid oxidation pathways in the brown fat cell. J Biol Chem 2001; 276: 1486-1493.
116. Lendoye E, Sibille B, Rousseau AS, Murdaca J, Grimaldi PA, Lopez P. PPARbeta activation induces rapid changes of both AMPK subunit expression and AMPK activation in mouse skeletal muscle. Mol Endocrinol 2011; 25: 1487-1498.
117. Barroso E, Rodríguez-Calvo R, Serrano-Marco L, Astudillo AM, Balsinde J, Palomer X et al. The PPARb/d activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1a-Lipin 1- PPARa pathway leading to increased fatty acid oxidation. Endocrinology 2011; 152: 1848-1859.
118. Lim JY, Oh MA, Kim WH, Sohn HY, Park SI. AMP-activated protein kinase inhibits TGF-b-induced fibrogenic response of hepatic stellate cells by targeting transcriptional coactivator p300. J Cell Physiol 2011; e-pub ahead of print 12 May 2011; doi: 10.1002/jcp.22824.
119. Kelly LJ, Vicario PP, Thompson GM, Candelore MR, Doebber TW, Ventre J et al. Peroxisome proliferator-activated receptors gamma and alpha mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression. Endocrinology 1998; 139: 4920-4927.
120. Lee WJ, Kim M, Park HS, Kin HS, Jeon MJ, Oh KS et al. AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARalpha and PGC-1. Biochem Biophys Res Commun 2006; 340: 291-295.